NR 546 Week 4 Midterm Exam
Advanced Psychopharmacology for the PMHNP
Aligned with 2025 Curriculum Standards | Due 2nd August 2025
Chamberlain University | Psychiatric-Mental Health Nurse Practitioner (PMHNP)
Advanced Psychopharmacology | Neurobiology | Evidence-Based Medication Management
Exam Composition: 75 multiple-choice questions distributed across four content domains.
Cognitive level distribution: ~30% recall, ~50% application, ~20% analysis. Approximately 75%
of items are scenario-based (clinical case presentations, medication adjustments, side-effect
management, lab value interpretations), with 25% direct (receptor affinities, half-lives, FDA
indications, pharmacokinetic definitions). PMHNP-specific focus on evidence-based prescribing
algorithms (APA, Maudsley) for treatment-resistant depression and schizophrenia, complex
polypharmacy scenarios involving cytochrome P450 enzyme interactions and dose adjustments,
and pharmacogenomic testing applications and ethical considerations. Each item includes four
options (A-D), one correct answer, and a concise rationale explaining why the correct option is
best and why distractors are incorrect.
Contents
Section 1: Neuropharmacology and Pharmacokinetics/Pharmacodynamics (Q1-Q15)
Section 2: Psychotropic Medications for Mood and Anxiety Disorders (Q16-Q35)
Section 3: Psychotropic Medications for Psychotic and Cognitive Disorders (Q36-Q55)
Section 4: Special Populations, Polypharmacy, and Adverse Effects (Q56-Q75)
NR 546 Week 4 Midterm - Advanced Psychopharmacology for the PMHNP (2025) Page 1
, Section 1: Neuropharmacology and Pharmacokinetics/Pharmacodynamics
Items 1-15 cover neurotransmitter pathophysiology (dopamine, serotonin, norepinephrine, GABA),
pharmacokinetic principles (half-life, steady state, bioavailability, first-pass metabolism, volume of distribution),
CYP450 enzyme interactions (CYP2D6, CYP3A4, CYP2C9, CYP1A2), pharmacogenomics (CYP2D6 poor
metabolizers), receptor affinities (D2, alpha-1, H1, 5-HT2C, muscarinic), and the blood-brain barrier.
Q1: Which neurotransmitter is primarily implicated in the pathophysiology of schizophrenia's
positive symptoms?
A. Serotonin
B. Dopamine (mesolimbic hyperactivity) [CORRECT]
C. Norepinephrine
D. GABA
Correct Answer: B
Rationale: Positive symptoms of schizophrenia (hallucinations, delusions) are linked to hyperactive mesolimbic
dopamine. Serotonin and norepinephrine are more associated with mood/anxiety, and GABA is inhibitory.
Q2: A patient begins fluoxetine 20 mg daily. How long does it typically take to reach steady-state
concentration?
A. 1-2 days
B. Approximately 4-5 half-lives (~4 weeks given fluoxetine's long half-life and active metabolite)
[CORRECT]
C. 12 hours
D. 1 year
Correct Answer: B
Rationale: Steady state is reached in ~4-5 half-lives; fluoxetine/norfluoxetine's long half-life (~4-16 days) means
steady state may take 4+ weeks. 1-2 days, 12 hours, and 1 year are incorrect.
Q3: The cytochrome P450 enzyme that metabolizes most SSRIs and is strongly inhibited by
fluoxetine/paroxetine is:
A. CYP1A2
B. CYP2D6 [CORRECT]
C. CYP3A4
D. CYP2C9
Correct Answer: B
Rationale: Fluoxetine and paroxetine are potent CYP2D6 inhibitors, raising levels of substrates like TCAs and
antipsychotics. CYP1A2 (smoking induces), CYP3A4 (many drug interactions), and CYP2C9 are different
isoenzymes.
NR 546 Week 4 Midterm - Advanced Psychopharmacology for the PMHNP (2025) Page 2
, Q4: Which pharmacokinetic parameter describes the fraction of administered drug reaching systemic
circulation unchanged?
A. Volume of distribution
B. Bioavailability [CORRECT]
C. Half-life
D. Clearance
Correct Answer: B
Rationale: Bioavailability is the fraction reaching systemic circulation. Volume of distribution reflects
distribution, half-life is elimination time, and clearance is removal rate.
Q5: A PMHNP prescribes a drug that is a substrate of CYP3A4. Concurrent use with carbamazepine
will most likely:
A. Increase substrate drug levels
B. Decrease substrate drug levels due to CYP3A4 induction [CORRECT]
C. Have no effect
D. Inhibit CYP3A4
Correct Answer: B
Rationale: Carbamazepine is a strong CYP3A4 inducer, lowering substrate drug levels. The opposite of
inhibition, this interaction can cause treatment failure.
Q6: First-pass metabolism primarily occurs in the:
A. Kidney
B. Liver [CORRECT]
C. Lung
D. Brain
Correct Answer: B
Rationale: Orally administered drugs undergo hepatic first-pass metabolism before systemic circulation. This
reduces bioavailability of many drugs and explains why oral doses often exceed parenteral doses.
Q7: A drug with high first-pass metabolism would have substantially higher bioavailability when
administered:
A. Orally
B. Sublingually or intravenously [CORRECT]
C. With food
D. At bedtime
Correct Answer: B
Rationale: Sublingual and IV routes bypass hepatic first-pass metabolism. Oral dosing with food or at bedtime
does not avoid first-pass effects.
NR 546 Week 4 Midterm - Advanced Psychopharmacology for the PMHNP (2025) Page 3
Advanced Psychopharmacology for the PMHNP
Aligned with 2025 Curriculum Standards | Due 2nd August 2025
Chamberlain University | Psychiatric-Mental Health Nurse Practitioner (PMHNP)
Advanced Psychopharmacology | Neurobiology | Evidence-Based Medication Management
Exam Composition: 75 multiple-choice questions distributed across four content domains.
Cognitive level distribution: ~30% recall, ~50% application, ~20% analysis. Approximately 75%
of items are scenario-based (clinical case presentations, medication adjustments, side-effect
management, lab value interpretations), with 25% direct (receptor affinities, half-lives, FDA
indications, pharmacokinetic definitions). PMHNP-specific focus on evidence-based prescribing
algorithms (APA, Maudsley) for treatment-resistant depression and schizophrenia, complex
polypharmacy scenarios involving cytochrome P450 enzyme interactions and dose adjustments,
and pharmacogenomic testing applications and ethical considerations. Each item includes four
options (A-D), one correct answer, and a concise rationale explaining why the correct option is
best and why distractors are incorrect.
Contents
Section 1: Neuropharmacology and Pharmacokinetics/Pharmacodynamics (Q1-Q15)
Section 2: Psychotropic Medications for Mood and Anxiety Disorders (Q16-Q35)
Section 3: Psychotropic Medications for Psychotic and Cognitive Disorders (Q36-Q55)
Section 4: Special Populations, Polypharmacy, and Adverse Effects (Q56-Q75)
NR 546 Week 4 Midterm - Advanced Psychopharmacology for the PMHNP (2025) Page 1
, Section 1: Neuropharmacology and Pharmacokinetics/Pharmacodynamics
Items 1-15 cover neurotransmitter pathophysiology (dopamine, serotonin, norepinephrine, GABA),
pharmacokinetic principles (half-life, steady state, bioavailability, first-pass metabolism, volume of distribution),
CYP450 enzyme interactions (CYP2D6, CYP3A4, CYP2C9, CYP1A2), pharmacogenomics (CYP2D6 poor
metabolizers), receptor affinities (D2, alpha-1, H1, 5-HT2C, muscarinic), and the blood-brain barrier.
Q1: Which neurotransmitter is primarily implicated in the pathophysiology of schizophrenia's
positive symptoms?
A. Serotonin
B. Dopamine (mesolimbic hyperactivity) [CORRECT]
C. Norepinephrine
D. GABA
Correct Answer: B
Rationale: Positive symptoms of schizophrenia (hallucinations, delusions) are linked to hyperactive mesolimbic
dopamine. Serotonin and norepinephrine are more associated with mood/anxiety, and GABA is inhibitory.
Q2: A patient begins fluoxetine 20 mg daily. How long does it typically take to reach steady-state
concentration?
A. 1-2 days
B. Approximately 4-5 half-lives (~4 weeks given fluoxetine's long half-life and active metabolite)
[CORRECT]
C. 12 hours
D. 1 year
Correct Answer: B
Rationale: Steady state is reached in ~4-5 half-lives; fluoxetine/norfluoxetine's long half-life (~4-16 days) means
steady state may take 4+ weeks. 1-2 days, 12 hours, and 1 year are incorrect.
Q3: The cytochrome P450 enzyme that metabolizes most SSRIs and is strongly inhibited by
fluoxetine/paroxetine is:
A. CYP1A2
B. CYP2D6 [CORRECT]
C. CYP3A4
D. CYP2C9
Correct Answer: B
Rationale: Fluoxetine and paroxetine are potent CYP2D6 inhibitors, raising levels of substrates like TCAs and
antipsychotics. CYP1A2 (smoking induces), CYP3A4 (many drug interactions), and CYP2C9 are different
isoenzymes.
NR 546 Week 4 Midterm - Advanced Psychopharmacology for the PMHNP (2025) Page 2
, Q4: Which pharmacokinetic parameter describes the fraction of administered drug reaching systemic
circulation unchanged?
A. Volume of distribution
B. Bioavailability [CORRECT]
C. Half-life
D. Clearance
Correct Answer: B
Rationale: Bioavailability is the fraction reaching systemic circulation. Volume of distribution reflects
distribution, half-life is elimination time, and clearance is removal rate.
Q5: A PMHNP prescribes a drug that is a substrate of CYP3A4. Concurrent use with carbamazepine
will most likely:
A. Increase substrate drug levels
B. Decrease substrate drug levels due to CYP3A4 induction [CORRECT]
C. Have no effect
D. Inhibit CYP3A4
Correct Answer: B
Rationale: Carbamazepine is a strong CYP3A4 inducer, lowering substrate drug levels. The opposite of
inhibition, this interaction can cause treatment failure.
Q6: First-pass metabolism primarily occurs in the:
A. Kidney
B. Liver [CORRECT]
C. Lung
D. Brain
Correct Answer: B
Rationale: Orally administered drugs undergo hepatic first-pass metabolism before systemic circulation. This
reduces bioavailability of many drugs and explains why oral doses often exceed parenteral doses.
Q7: A drug with high first-pass metabolism would have substantially higher bioavailability when
administered:
A. Orally
B. Sublingually or intravenously [CORRECT]
C. With food
D. At bedtime
Correct Answer: B
Rationale: Sublingual and IV routes bypass hepatic first-pass metabolism. Oral dosing with food or at bedtime
does not avoid first-pass effects.
NR 546 Week 4 Midterm - Advanced Psychopharmacology for the PMHNP (2025) Page 3
